Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

DIAMANTOPOULOS, Alex et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. In: PharmacoEconomics, 2014, vol. 32, n° 8, p. 775–787. doi: 10.1007/s40273-014-0165-7

Article (Published version)

Identifiers

PID : unige:45947
DOI : 10.1007/s40273-014-0165-7
PMID : 24854959

Journal ISSN1179-2027

482views

461downloads

Creation27/01/2015 15:35:00

First validation27/01/2015 15:35:00

Update time24/01/2025 14:34:13

Status update24/01/2025 14:34:13

Last indexation24/01/2025 14:42:14

Archive ouverte UNIGE

Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK

Since receiving a positive recommendation in England, Wales and Scotland, tocilizumab (TCZ) is one of the options available to clinicians for the treatment of rheumatoid arthritis (RA) patients in the UK.

Technical informations